Company / Working Capital
LENZ Therapeutics, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$280.2M
FY2025
5-year range
$48.7M / $369.6M
FY2021-FY2025
Trend
+39.1%
vs FY2024
Sector context
#149 of 213
Health Care
What the data says
At $280M, LENZ Therapeutics, Inc.'s working capital ranks #149 of 213 in the Health Care sector. Improved from $49M to $280M over the past 2 years.
Based on SEC 10-K filings.
$280M in FY2025 with a 3-year CAGR of +2.2%.
Improved from $49M to $280M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +2.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#149 of 213 in Health CareTop 70% of 213This company $280.2M Sector average $934.6M
▼
-70.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +2.2%, indicating consistent growth.
- In FY2025, working capital increased 39.1% year-over-year.
- Ranks #149 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $280.2M | +39.1% |
| FY2024 | $201.5M | +313.5% |
| FY2023 | $48.7M | -81.4% |
| FY2022 | $262.3M | -29.0% |
| FY2021 | $369.6M | +3476.8% |
| FY2020 | -$10.9M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026